MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.23
-0.31
-4.74%
After Hours: 6.38 +0.15 +2.41% 18:02 09/23 EDT
OPEN
6.68
PREV CLOSE
6.54
HIGH
6.86
LOW
6.17
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
7.09
52 WEEK LOW
1.210
MARKET CAP
429.17M
P/E (TTM)
-5.3893
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its Board of Directors, effective October 1, 2020. Ms. Giles will serve
PR Newswire · 1d ago
CymaBay Therapeutics to Present at Upcoming Investor Conferences
NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor
GlobeNewswire · 09/03 20:05
The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 12:02
CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study In Primary Biliary Cholangitis At The Digital International Liver Congress 2020
Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosis   Self-reported pruritus improved at one year for patients in highest categories of baseline itch Selected
Benzinga · 08/27 12:01
The Week Ahead In Biotech (Aug. 24-29): Lipocine Binary Event, Liver Congress In The Spotlight
After seeing some strength earlier on, biotech stocks came under pressure in the week ended Aug. 21.
Benzinga · 08/23 17:20
No other industry has more at stake this election than health care. Here's how pros are playing it
Investors may be overly concerned about the impact of the presidential election on health care stocks, analysts say.
CNBC.com · 08/20 13:25
CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress 2020
GlobeNewswire · 08/20 13:00
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 08/11 12:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBAY. Analyze the recent business situations of CymaBay through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBAY stock price target is 12.80 with a high estimate of 20.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 190
Institutional Holdings: 75.00M
% Owned: 108.87%
Shares Outstanding: 68.89M
TypeInstitutionsShares
Increased
31
7.33M
New
60
5.82M
Decreased
33
12.53M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Independent Director
Robert Wills
President/Chief Executive Officer/Director/IR Contact Officer
Sujal Shah
Senior Vice President/Chief Scientific Officer
Charles McWherter
Chief Compliance Officer
Klara Dickinson
Vice President - Finance
Daniel Menold
Independent Director
Caroline Loewy
Independent Director
Paul Truex
Independent Director
Kurt von Emster
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.